Zhejiang Medicine Stock Forum

Despite declining earnings per share, market sentiment for Zhejiang Medicine remains steady. The company's disappointing performance over the past year and five years suggests potential long-term share price weakness.

Despite expected EPS rise, Zhejiang Medicine's P/E ratio stays below market, indicating shareholder skepticism. Future earnings could be volatile with potential unseen threats preventing P/E ratio from reflecting positive outlook.

Zhejiang Medicine exhibits notable earnings growth due to business reinvestment, despite a low return rate. Effectively managing its retained profits (69%), the company's earnings are expected to accelerate according to analysts.